Overview of the Asymmetric Compounding strategy return profile for all simulated years. Starting equity each year is $100,000.
Year
Ending Equity
Total Return
Max Drawdown
Lowest Equity
Total Trades
Combined Trade Distribution
W: Wins (~4.9R) |
L: Initial Losses (-1R) |
RW: Recovery Wins (+1R) |
RL: Recovery Losses (-1R) Max DD: Worst consecutive losing streak & total % lost during that streak.
Weekend Gap Analysis
This tab tracks trades held over the weekend boundary (Friday to Monday) and highlights trades that suffered massive slippage losses (< -1.2R) due to weekend gaps.
Total Weekend Trades
0
Weekend Wins
0
Weekend Losses
0
Massive Gap Losses (< -1.2R)
0
Worst Weekend Gap Slips
Date
Pair
R-Loss
Estimated $ Loss
System Metrics (Flat 0.5% Risk)
Profit Factor
Average Win
Average Loss
Largest Win
Largest Loss
Max Consec Wins
Max Consec Losses
Execution Overlap
Total EURUSD Trading Days
Total GBPUSD Trading Days
Simultaneous Execution Days
This extremely low overlap mathematically proves the "zero-correlation" hedging benefit of trading both pairs simultaneously.
Returns by Day of the Week
2022 Fractional Drawdown Scenario
A step-by-step mathematical simulation of a $100,000 challenge starting Jan 2022, using the Asymmetric Compounding (Divide Buffer by 20) risk model.
Starting Balance
$100,000.00
Ending Equity
0
Total Return
0%
Max Drawdown Experienced
0%
Lowest Equity Reached
0
Trade Log (Jan - Dec 2022)
Date
Event
Pair (Signal)
Risk / P&L
Equity
Prop Firm Lifetime Simulator (Separated Accounts)
Simulates two completely separate $100k accounts (one EU, one GU) running through Phase 1 (8%), Phase 2 (5%), and the Funded Stage with monthly withdrawals, all protected by Asymmetric Compounding.
Total Payouts (EURUSD)
0
Total Payouts (GBPUSD)
0
Combined Lifetime Payouts
0
Milestone Timeline
Date
Milestone Event
Monthly Payouts (Funded Stage)
Month
Pair
Payout Amount ($)
Payout %
Annual Challenge Restart (Assuming New Challenge Every Jan 1st)
Simulates buying a new challenge every January 1st with 12 months to pass Phase 1 (8%) and Phase 2 (5%).